233 related articles for article (PubMed ID: 30075973)
21. Standardized uptake value based evaluation of lymphoma by FDG and FLT PET/CT.
Wang R; Zhu H; Chen Y; Li C; Li F; Shen Z; Tian J; Yu L; Xu B
Hematol Oncol; 2014 Sep; 32(3):126-32. PubMed ID: 23996464
[TBL] [Abstract][Full Text] [Related]
22. FDG positron emission tomography/computed tomography scan may identify mantle cell lymphoma patients with unusually favorable outcome.
Karam M; Ata A; Irish K; Feustel PJ; Mottaghy FM; Stroobants SG; Verhoef GE; Chundru S; Douglas-Nikitin V; Oliver Wong CY; Brepoels LM
Nucl Med Commun; 2009 Oct; 30(10):770-8. PubMed ID: 19657307
[TBL] [Abstract][Full Text] [Related]
23. Variety in bone marrow 18F-FDG uptake in Hodgkin lymphoma patients without lymphomatous bone marrow involvement: does it have an explanation?
Adams HJ; de Klerk JM; Fijnheer R; Heggelman BG; Dubois SV; Nievelstein RA; Kwee TC
Nucl Med Commun; 2016 Jan; 37(1):23-9. PubMed ID: 26440567
[TBL] [Abstract][Full Text] [Related]
24. The value of FDG PET/CT in the initial staging and bone marrow involvement of patients with multiple myeloma.
Sager S; Ergül N; Ciftci H; Cetin G; Güner SI; Cermik TF
Skeletal Radiol; 2011 Jul; 40(7):843-7. PubMed ID: 21229354
[TBL] [Abstract][Full Text] [Related]
25. Whole-body MRI, FDG-PET/CT, and bone marrow biopsy, for the assessment of bone marrow involvement in patients with newly diagnosed lymphoma.
Albano D; Patti C; Lagalla R; Midiri M; Galia M
J Magn Reson Imaging; 2017 Apr; 45(4):1082-1089. PubMed ID: 27603267
[TBL] [Abstract][Full Text] [Related]
26. Pre-treatment [
Chen J; Zhao Y
Hematology; 2024 Dec; 29(1):2325317. PubMed ID: 38465661
[TBL] [Abstract][Full Text] [Related]
27. Prognostic value of bone marrow
Lee JW; Lee SC; Kim HJ; Lee SM
Hell J Nucl Med; 2017; 20(1):17-25. PubMed ID: 28315904
[TBL] [Abstract][Full Text] [Related]
28. 18-F-fluorodeoxyglucose-positron emission tomography as a new approach to detect lymphomatous bone marrow.
Moog F; Bangerter M; Kotzerke J; Guhlmann A; Frickhofen N; Reske SN
J Clin Oncol; 1998 Feb; 16(2):603-9. PubMed ID: 9469348
[TBL] [Abstract][Full Text] [Related]
29. PET/CT predicts bone marrow involvement in paediatric non-Hodgkin lymphoma and may preclude the need for bone marrow biopsy in selected patients.
Chen S; Wang S; He K; Ma C; Fu H; Wang H
Eur Radiol; 2018 Jul; 28(7):2942-2950. PubMed ID: 29383519
[TBL] [Abstract][Full Text] [Related]
30. Recurrent Marginal Zone Lymphoma with Bone Marrow Involvement Detected by ¹⁸F-FDG PET/CT and Biopsy: A Diagnostic Challenge.
Hsiao YS; Shen SC; Hsiao SC
Am J Case Rep; 2024 Apr; 25():e943275. PubMed ID: 38644602
[TBL] [Abstract][Full Text] [Related]
31. Prognostic impact of 18F-fluoro-deoxyglucose positron emission tomography in untreated mantle cell lymphoma: a retrospective study from the GOELAMS group.
Bodet-Milin C; Touzeau C; Leux C; Sahin M; Moreau A; Maisonneuve H; Morineau N; Jardel H; Moreau P; Gallazini-Crépin C; Gries P; Gressin R; Harousseau JL; Mohty M; Moreau P; Kraeber-Bodere F; Le Gouill S
Eur J Nucl Med Mol Imaging; 2010 Aug; 37(9):1633-42. PubMed ID: 20428863
[TBL] [Abstract][Full Text] [Related]
32. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
33. F-18 FDG PET for evaluation of bone marrow involvement in non-Hodgkin lymphoma: a meta-analysis.
Chen YK; Yeh CL; Tsui CC; Liang JA; Chen JH; Kao CH
Clin Nucl Med; 2011 Jul; 36(7):553-9. PubMed ID: 21637057
[TBL] [Abstract][Full Text] [Related]
34. Can [18F]fluorodeoxyglucose positron emission tomography imaging complement biopsy results from the iliac crest for the detection of bone marrow involvement in patients with malignant lymphoma?
Fuster D; Chiang S; Andreadis C; Guan L; Zhuang H; Schuster S; Alavi A
Nucl Med Commun; 2006 Jan; 27(1):11-5. PubMed ID: 16340718
[TBL] [Abstract][Full Text] [Related]
35. Application of 18F-fluorodeoxyglucose positron emission tomography/computerized tomography in mantle cell lymphoma.
Yang S; Fu L; AbuduRxiti M; Wu J; Wang Q; Qin Y; Zou X; Li H
Nucl Med Commun; 2020 May; 41(5):477-484. PubMed ID: 32168265
[TBL] [Abstract][Full Text] [Related]
36. Can FDG-PET/CT replace blind bone marrow biopsy of the posterior iliac crest in Ewing sarcoma?
Kasalak Ö; Glaudemans AWJM; Overbosch J; Jutte PC; Kwee TC
Skeletal Radiol; 2018 Mar; 47(3):363-367. PubMed ID: 29124298
[TBL] [Abstract][Full Text] [Related]
37. Fluorodeoxyglucose-Positron Emission Tomography Predicts Bone Marrow Involvement in the Staging of Follicular Lymphoma.
St-Pierre F; Broski SM; LaPlant BR; Maurer MJ; Ristow K; Thanarajasingam G; Macon WR; Habermann TM; Witzig TE
Oncologist; 2020 Aug; 25(8):689-695. PubMed ID: 32319706
[TBL] [Abstract][Full Text] [Related]
38. Fluorodeoxyglucose positron emission tomography (FDG-PET) and PET/computed tomography imaging characteristics of thyroid lymphoma and their potential clinical utility.
Basu S; Li G; Bural G; Alavi A
Acta Radiol; 2009 Mar; 50(2):201-4. PubMed ID: 19089692
[TBL] [Abstract][Full Text] [Related]
39. FDG PET/CT may replace bone marrow biopsy for the evaluation of bone marrow involvement in selected mature T- and natural killer-cell lymphomas: A meta-analysis.
Guo L; Wang R; Hou N; Kuang A; Shen G
Eur J Radiol; 2024 Mar; 172():111353. PubMed ID: 38320330
[TBL] [Abstract][Full Text] [Related]
40. Characterizing bone marrow involvement in Hodgkin's lymphoma by FDG-PET/CT.
Weiler-Sagie M; Kagna O; Dann EJ; Ben-Barak A; Israel O
Eur J Nucl Med Mol Imaging; 2014 Jun; 41(6):1133-40. PubMed ID: 24570095
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
